A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.
Tang H, Xiao G, Behrens C, Schiller J, Allen J, Chow CW, Suraokar M, Corvalan A, Mao J, White MA, Wistuba II, Minna JD, Xie Y.
Tang H, et al.
Clin Cancer Res. 2013 Mar 15;19(6):1577-86. doi: 10.1158/1078-0432.CCR-12-2321. Epub 2013 Jan 28.
Clin Cancer Res. 2013.
PMID: 23357979
Free PMC article.
The predicted benefit group showed significant improvement in survival after ACT (UT Lung SPORE data: HR = 0.34, P = 0.017; JBR.10 clinical trial data: HR = 0.36, P = 0.038), whereas the predicted nonbenefit group showed no survival benefit for 2 datasets (HR = 0.80, P = 0 …
The predicted benefit group showed significant improvement in survival after ACT (UT Lung SPORE data: HR = 0.34, P = 0.017; JBR.10 cl …